Arthritis Research & Therapy· 2026Q1
HLA-B*27-associated arthritis across the ages – bridging the gap
- 0citations
- Q1SCImago
- 2026year
Short summary
Pathogenesis of HLA-B*27-associated arthritis appears similar across pediatric and adult age groups, suggesting a unified understanding may inform future treatments.
AI-generated from the title and abstract; the full text is not read.
Key points
- HLA-B*27-associated arthritis encompasses various inflammatory arthritic forms under the spondyloarthritis umbrella.
- Clinical manifestations and outcomes of this condition vary significantly with age.
- Separate classification systems exist for pediatric and adult forms of the disease.
- The fundamental pathogenesis involving HLA-B*27 is thought to be consistent across the age spectrum.
- Advances in understanding HLA-B*27's pathogenic role may lead to new treatment options.
AI-generated from the title and abstract; the full text is not read.
Abstract
HLA-B*27-associated arthritis comprises a number of different forms of inflammatory arthritis with a common phenotype, encompassed by the term spondyloarthritis. The clinical features and outcomes differ across the age spectrum which has resulted in different classification systems being applied to paediatric and adult disease. However, the pathogenesis of spondyloarthritis related to HLA-B*27 appears similar across the ages and recent advances in our understanding of the role of HLA-B*27 in the pathogenesis of spondyloarthritis may influence future treatment options.
The authors' abstract, as published at the source. Arthritis Research & Therapy, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Rheumatology
RheumatologyMedicine